Literature DB >> 17951021

Smoking cessation treatment in community-based substance abuse rehabilitation programs.

Malcolm S Reid1, Bryan Fallon, Susan Sonne, Frank Flammino, Edward V Nunes, Huiping Jiang, Eva Kourniotis, Jennifer Lima, Ron Brady, Cynthia Burgess, Cynthia Arfken, Eric Pihlgren, Louis Giordano, Aron Starosta, James Robinson, John Rotrosen.   

Abstract

Nicotine dependence is highly prevalent among drug- and alcohol-dependent patients. A multisite clinical trial of smoking cessation (SC) treatment was performed at outpatient community-based substance abuse rehabilitation programs affiliated with the National Drug Abuse Treatment, Clinical Trials Network. Cigarette smokers (N=225) from five methadone maintenance programs and two drug and alcohol dependence treatment programs were randomly assigned in a 2:1 ratio to receive either (1) SC treatment as an adjunct to substance abuse treatment-as-usual (TAU) or (2) substance abuse TAU. Smoking cessation treatment consisted of 1 week of group counseling before the target quit date and 8 weeks of group counseling plus transdermal nicotine patch treatment (21 mg/day for Weeks 1-6 and 14 mg/day for Weeks 7 and 8) after the target quit date. Smoking abstinence rates in SC, 10%-11% during treatment and 5%-6% at the 13- and 26-week follow-up visits, were significantly better than those in TAU during treatment (p< .01). In addition, SC was associated with significantly greater reductions as compared with TAU in cigarettes smoked per day (75% reduction, p< .001), exhaled carbon monoxide levels (p< .001), cigarette craving (p< .05), and nicotine withdrawal (p< .05). Smoking cessation did not differ from TAU on rates of retention in substance abuse treatment, abstinence from primary substance of abuse, and craving for primary substance of abuse. Compliance with SC treatment, moderate at best, was positively associated with smoking abstinence rates. Smoking cessation treatment resulted in significant reductions in daily smoking and modest smoking abstinence rates without having an adverse impact on substance abuse rehabilitation when given concurrently with outpatient substance abuse treatment. Substance abuse treatment programs should not hesitate to implement SC for established patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17951021     DOI: 10.1016/j.jsat.2007.08.010

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  60 in total

1.  Multisite effectiveness trials of treatments for substance abuse and co-occurring problems: have we chosen the best designs?

Authors:  Edward V Nunes; Samuel Ball; Robert Booth; Gregory Brigham; Donald A Calsyn; Kathleen Carroll; Daniel J Feaster; Denise Hien; Robert L Hubbard; Walter Ling; Nancy M Petry; John Rotrosen; Jeffrey Selzer; Maxine Stitzer; Susan Tross; Paul Wakim; Theresa Winhusen; George Woody
Journal:  J Subst Abuse Treat       Date:  2010-06

2.  How is tobacco treatment provided during drug treatment?

Authors:  Jamie J Hunt; A Paula Cupertino; Susan Garrett; Peter D Friedmann; Kimber P Richter
Journal:  J Subst Abuse Treat       Date:  2011-08-09

3.  Understanding the drug treatment community's ambivalence towards tobacco use and treatment.

Authors:  Kimber P Richter; Jamie J Hunt; A Paula Cupertino; Susan Garrett; Peter D Friedmann
Journal:  Int J Drug Policy       Date:  2012-01-26

4.  Design considerations for a study to evaluate the impact of smoking cessation treatment on stimulant use outcomes in stimulant-dependent individuals.

Authors:  Theresa Winhusen; Maxine Stitzer; George Woody; Gregory Brigham; Frankie Kropp; Udi Ghitza; Robert Lindblad; Bryon Adinoff; Cindy Green; Gaurav Sharma; Eugene Somoza
Journal:  Contemp Clin Trials       Date:  2011-10-08       Impact factor: 2.226

5.  Early quit days among methadone-maintained smokers in a smoking cessation trial.

Authors:  Marcel A de Dios; Bradley J Anderson; Celeste M Caviness; Michael D Stein
Journal:  Nicotine Tob Res       Date:  2014-06-20       Impact factor: 4.244

Review 6.  Treating tobacco use disorder in pregnant women in medication-assisted treatment for an opioid use disorder: a systematic review.

Authors:  Sarah C Akerman; Mary F Brunette; Alan I Green; Daisy J Goodman; Heather B Blunt; Sarah H Heil
Journal:  J Subst Abuse Treat       Date:  2014-12-22

Review 7.  Are Pharmacotherapies Ineffective in Opioid-Dependent Smokers? Reflections on the Scientific Literature and Future Directions.

Authors:  Mollie E Miller; Stacey C Sigmon
Journal:  Nicotine Tob Res       Date:  2015-08       Impact factor: 4.244

8.  Medical and Mental Health Status Among Drug Dependent Patients Participating in a Smoking Cessation Treatment Study.

Authors:  Jennifer E Lima; Malcolm S Reid; Jennifer L Smith; Yulei Zhang; Huiping Jiang; John Rotrosen; Edward Nunes
Journal:  J Drug Issues       Date:  2009-03

9.  Beyond drug use: a systematic consideration of other outcomes in evaluations of treatments for substance use disorders.

Authors:  Stephen T Tiffany; Lawrence Friedman; Shelly F Greenfield; Deborah S Hasin; Ron Jackson
Journal:  Addiction       Date:  2011-10-07       Impact factor: 6.526

10.  E-cigarette knowledge, attitudes, and use in opioid dependent smokers.

Authors:  Michael D Stein; Celeste M Caviness; Kristin Grimone; Daniel Audet; Allison Borges; Bradley J Anderson
Journal:  J Subst Abuse Treat       Date:  2014-11-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.